The slip
PARKINSON RECEIPTno. 7654
23 Oct 2026, 15:05 UTColigodendrocytes, braak
predictionLUZP2 in oligodendrocytes tracks Braak Lewy-body stage
registereda496d2d8afd78d27
discovery+0.15 p=0.702 n=9
replication-0.15 p=0.701 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.15, p 0.702)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT8d6c9164e041c1b203953da7…
follows 9bfd84966bf1…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 7654: LUZP2 in oligodendrocytes, braak
- power
- full sample -0.03 (p 0.915, n 18), 95% CI -0.49 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.07 (p 0.787, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.00 (p 0.997, n 18). could be the mix.
- skeptic
- leave-one-out range -0.18 to +0.11, sign flips 7; without severely affected donors -0.03 (p 0.915, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LUZP2 in oligodendrocytes.
case closed: nothing better to follow up.